Deutsche Bank AG Sells 1,653 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)

Deutsche Bank AG lowered its holdings in Bicycle Therapeutics plc (NASDAQ:BCYC) by 20.5% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,417 shares of the company’s stock after selling 1,653 shares during the period. Deutsche Bank AG’s holdings in Bicycle Therapeutics were worth $90,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Baker BROS. Advisors LP increased its position in Bicycle Therapeutics by 15.8% during the 4th quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company’s stock worth $152,395,000 after purchasing an additional 1,485,397 shares in the last quarter. Candriam S.C.A. grew its position in Bicycle Therapeutics by 3.5% in the 4th quarter. Candriam S.C.A. now owns 1,087,876 shares of the company’s stock worth $15,230,000 after purchasing an additional 37,278 shares in the last quarter. Long Focus Capital Management LLC bought a new position in shares of Bicycle Therapeutics during the 4th quarter valued at approximately $7,603,000. Bank of America Corp DE grew its position in shares of Bicycle Therapeutics by 2.1% during the 4th quarter. Bank of America Corp DE now owns 392,859 shares of the company’s stock valued at $5,500,000 after acquiring an additional 7,994 shares during the period. Finally, Platinum Investment Management Ltd. lifted its stake in shares of Bicycle Therapeutics by 13.6% during the 4th quarter. Platinum Investment Management Ltd. now owns 309,059 shares of the company’s stock valued at $4,327,000 after buying an additional 36,910 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have issued reports on BCYC. Morgan Stanley set a $17.00 target price on shares of Bicycle Therapeutics and gave the stock an “equal weight” rating in a research note on Monday, May 5th. B. Riley reduced their target price on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a “neutral” rating on the stock in a report on Friday, May 2nd. Barclays cut their price target on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, May 1st. JMP Securities dropped their target price on shares of Bicycle Therapeutics from $26.00 to $22.00 and set a “market outperform” rating for the company in a research report on Friday, May 2nd. Finally, Royal Bank of Canada dropped their target price on shares of Bicycle Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a research report on Friday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Bicycle Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Bicycle Therapeutics Price Performance

BCYC opened at $8.30 on Wednesday. The firm has a market cap of $574.81 million, a P/E ratio of -2.52 and a beta of 1.60. Bicycle Therapeutics plc has a 1-year low of $6.10 and a 1-year high of $28.67. The company has a 50 day simple moving average of $7.96 and a two-hundred day simple moving average of $11.92.

Bicycle Therapeutics (NASDAQ:BCYC) last released its earnings results on Thursday, May 1st. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The company had revenue of $9.98 million during the quarter, compared to analysts’ expectations of $8.67 million. Equities analysts anticipate that Bicycle Therapeutics plc will post -3.06 earnings per share for the current year.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.